Secondary Logo

Journal Logo

Borderline Personality Disorder in Patients With Medical Illness

A Review of Assessment, Prevalence, and Treatment Options

Doering, Stephan MD

doi: 10.1097/PSY.0000000000000724
CLINICAL APPLICATIONS
Free

Objective Borderline personality disorder (BPD) occurs in 0.7% to 3.5% of the general population. Patients with BPD experience excessive comorbidity of psychiatric and somatic diseases and are known to be high users of health care services. Because of a range of challenges related to adverse health behaviors and their interpersonal style, patients with BPD are often regarded as “difficult” to interact with and treat optimally.

Methods This narrative review focuses on epidemiological studies on BPD and its comorbidity with a specific focus on somatic illness. Empirically validated treatments are summarized, and implementation of specific treatment models is discussed.

Results The prevalence of BPD among psychiatric inpatients (9%–14%) and outpatients (12%–18%) is high; medical service use is very frequent, annual societal costs vary between €11,000 and €28,000. BPD is associated with cardiovascular diseases and stroke, metabolic disease including diabetes and obesity, gastrointestinal disease, arthritis and chronic pain, venereal diseases, and HIV infection as well as sleep disorders. Psychotherapy is the treatment of choice for BPD. Several manualized treatments for BPD have been empirically validated, including dialectical behavior therapy, transference-focused psychotherapy, mentalization-based therapy, and schema-focused therapy.

Conclusions Health care could be substantially improved if all medical specialties would be familiar with BPD, its pathology, medical and psychiatric comorbidities, complications, and treatment. In mental health care, several empirically validated treatments that are applicable in a wide range of clinical settings are available.

From the Department of Psychoanalysis and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Address correspondence to Stephan Doering, MD, Department of Psychoanalysis and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. E-mail: stephan.doering@meduniwien.ac.at

Received for publication September 1, 2018; revision received May 1, 2019.

Online date: June 20, 2019

Back to Top | Article Outline

CLINICAL CASE1

A 26-year-old woman presents at the emergency care unit with severe hypoglycemia. She has been diagnosed as having type 1 diabetes at the age of 19 years and is on an intensive insulin regimen. During the previous 18 months, she was admitted to the emergency department 12 times because of hypoglycemia or hyperosmolar hyperglycemic state. The laboratory tests yielded highly increased hemoglobin A1c levels. The resident on duty spoke to her about her insulin regimen and her suboptimal adherence. In response, she immediately became furious and yelled at the resident. Afterward, she refused to talk to him again. The following morning, the senior physician talked with the patient and managed to establish a better contact with her. It became clear that the patient had dropped out of five previous psychotherapies already. She mentioned that “The therapists were all nonsense.” In addition, she was admitted to psychiatry 17 times because of suicide attempts and other crisis situations. She was repeatedly diagnosed as having borderline personality disorder (BPD). However, she had never received treatment that directly addressed borderline personality.

Upon admission, she understood that her health behavior and her frequent diabetes-related complications were probably associated with her impulsivity and personality problems. She agreed to see a psychiatrist, who admitted her to a specialized borderline personality unit in a nearby town. After 3 weeks of inpatient treatment, she was referred for individual psychotherapy. She managed to maintain a good therapeutic relationship with her therapist, and her diabetes complications disappeared in the subsequent 2 years. She started an apprenticeship as an accountant and engaged in a partnership that was much more stable than her earlier relationships.

BPD is a severe mental disorder that affects 0.7% to 3.5% of the general population (1–4). Impairment in the realms of regulation of emotions and impulses, identity, and interpersonal relationships cause major problems in social adaptation (5) and quality of life (6). Because of frequent self-harming behavior and suicide attempts (7), high medical and mental health service utilization (5,8), low compliance (9), and negative life-style and health-related behaviors (10), patients with BPD often experience considerable medical comorbidities (e.g., diabetes mellitus) and are seen frequently in all medical specialties. Patients with BPD are regarded to be “difficult,” those who challenge the health care provider’s interpersonal skills, those who are time-consuming and noncompliant, and those who drop out of treatment frequently (11).

Back to Top | Article Outline

DIAGNOSIS

The Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition; DSM-5) (12) contains two diagnostic approaches, a categorical one and a hybrid dimensional model consisting of personality functioning (PF) and personality traits. The primary approach of the DSM-5, section II, consists of general and specific criteria that both have to be fulfilled for the diagnosis of a personality disorder (PD). The former refer to the domains of the personality affected, inflexibility, distress, and chronicity of the condition. The specific diagnostic criteria of BPD are given in Figure 1.

FIGURE 1

FIGURE 1

The so-called Alternative DSM-5 Model for Personality Disorders (AMPD) (12, p. 761 ff.) contains as the first general diagnostic criterion, specifying an impairment in PF with specific patterns of impairment for the different specific PDs. Moreover, the AMPD comprises five PD trait domains with a certain number of facets each. The five domains are as follows: a) negative affectivity, b) detachment, c) antagonism, d) disinhibition, and e) psychoticism. From the impairment of PF and specific patterns of trait domains and facets, six individual PDs are defined, and in addition, a trait-specified description of every other combination of personality pathology can be composed. The description of BPD according to the AMPD is displayed in Figure 2.

FIGURE 2

FIGURE 2

The diagnosis of BPD is usually made clinically by experienced specialists; however, the use of psychological tests—questionnaires or structured interviews—is helpful to assure the diagnosis. Because the BPD diagnostic criteria for the categorical diagnosis have not been changed in DSM-5 (12), the instruments using Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (13) criteria can still be used. Because of their lack of reliability, questionnaires are not suited for making a diagnosis, but they can be used as screening tools. Well-established instruments are the Personality Disorder Questionnaire-4+ (14,15) or the Assessment of DSM-5 Personality Disorders (16). For the evaluation of changes in borderline symptoms, the Borderline Symptom List (17) has been developed. All three questionnaires can be obtained from the authors or downloaded free of charge on the internet. For the assessment of the new AMPD of the DSM-5, recently the Levels of Personality Functioning Self-Report (18) and the Personality Inventory for DSM-5 (19) have been published.

Structured interviews are much more reliable for diagnosing PDs than self-report instruments. A well-established measure is the Structured Clinical Interview for DSM-5 Personality Disorders (20), which is regarded as a criterion standard for research purposes.

Back to Top | Article Outline

EPIDEMIOLOGY

Prevalence and Costs

The point prevalence of BPD in the general population has been assessed in many studies with strong methodology; a number of large-scale surveys of the 21st century yielded between 0.7% and 3.5% (2–5,21–25). Although the consensus is that clinical BPD diagnoses are more common in women than in men (12, p. 666), evidence suggests that there are no marked sex differences in the prevalence of BPD in the community; female BPD patients are more prone to use mental health care services than male ones (2,3,24,25). Among primary care patients, BPD occurred in 6.4% (lifetime diagnosis) (26) and even 19% when diagnosed as having a questionnaire (27). In psychiatric outpatients, BPD occurs in 9.3% to 14.4% (28,29) and in 9% in psychiatric emergency services (30). Psychiatric inpatients are diagnosed as having BPD in 12% to 18% (31–33).

Between 60% and 80% of BPD patients attempt suicide during their lives (7,34); up to 10% die of suicide (7,31,35). Self-harming behavior occurs in 90% of the borderline patients during lifetime (7).

Patients with BPD show very high medical and mental health service use. Outpatient psychosocial treatment is used by 70% to 95% of all BPD patients during lifetime (3,36,37), the numbers of lifetime psychiatric inpatient treatment differ vastly and range from 13.4% in a British sample (38) up to 72% to 79% in patients from the United States (5,36,37). In the United States, more than 60% receive psychopharmacological medication during lifetime (5,36), with 40% taking more than three drugs at the same time (37). Reliable numbers regarding medical service use of BPD patients do not exist; however, it has been shown repeatedly that service use is increased compared with other psychiatric diagnostic groups (8,39) and with the general population (38,40). The increased service use and psychosocial impairment results in considerable direct and indirect costs. Several large-scale surveys yielded annual health care costs of €8508 in Germany (41) and total societal costs of €11,308 in Spain (42), €16,852 in the Netherlands (43), and €28,026 in Germany (44). In 1998, it was estimated that BPD patients generate 24% of the total costs of psychiatric inpatient treatment in Germany (45). Evidence-based psychotherapy has been determined to reduce annual costs by nearly €3000 in the Netherlands (46).

BPD goes along with severely impaired social and physical functioning (5,6,47–49), disability (4,25), and reduced quality of life (6). These impairments seem to be dependent on the presence of comorbid axis I disorders (3,38). However, it remains unclear whether functional impairment/disability is the consequence of comorbid axis I disorders or whether both functional impairment and axis I comorbidity are (independent) manifestations of a more severe underlying personality pathology. Interestingly, during the course of the disorder, symptoms tend to remit, but in many cases, impaired functioning persists, even after treatment (50). This is a relevant example that illustrates why DSM-5 has abandoned the multiaxial model that implied an (relative) independence of, for example, axes I and II. The new DSM-5 alternative model of PDs (Figure 2) refines this approach by diagnosing in a dimensional way instead of a categorical approach on different axes. Patients rather have one condition with personality and psychopathology in a highly individualized combination than a number of different and independent disorders.

Back to Top | Article Outline

Comorbidity—Psychiatric Disorders

Many studies have investigated the comorbidity of BPD. It has become clear that a “monomorbid BPD patient” is a relative rarity. Comorbidity of axis I disorders has been found in 84.5% (3), and that of axis II disorders has been found in 73.9% (25); the mean number of lifetime axis I diagnoses of BPD patients is 4.1; for axis II, it is 1.9 (51). Comorbid mood disorders occur in 50% to 60% of all BPD patients (4,25) with 93% lifetime diagnoses (52). Anxiety disorders (including posttraumatic stress disorder) have been found in 60% to 80% (25,53) with 88.4% lifetime diagnoses (52). The comorbidity of posttraumatic stress disorder is of particular importance in BPD patients because many have experienced maltreatment in childhood: it varies between 31.6% and 55.9% (25,51,52). Substance use disorders have been reported in slightly greater than 50% of BPD patients (25,51), with a lifetime rate of 64.1% (52). Eating disorders do also occur frequently in BPD patients; anorexia nervosa was found in 7% to 21%, and bulimia nervosa was found in 13% to 31% of all BPD patients (51,54,55). BPD has been found in 10% of somatization disorder patients (56,57); in 34.4% of BPD patients, comorbid somatization disorder was diagnosed (58).

Back to Top | Article Outline

ComorbiditySomatic Illness

From a psychosomatic viewpoint, the comorbidity of BPD with somatic diseases is of particular importance. It is well known that BPD increases the risk of numerous medical (somatic) conditions considerably. Moreover, BPD can complicate the course of several diseases (59). This pattern can be attributed in part to the poor health-related behavior and life-style. BPD patients are known to smoke and consume alcohol and drugs, as well as abuse sleep and pain medication frequently. Moreover, they tend to show a lack of physical exercise (10,60). In addition, BPD goes along with a negative perception of health, which itself might impair health-related behaviors (61).

Patients with BPD show poor adherence to psychological and medical treatment recommendations (9,62), and they tend to engage in disruptive behaviors such as “yelling, screaming, verbally threatening, and refusing to talk with medical staff” (63), and sabotage their medical treatment (11,64), for example, by preventing wounds from healing (64–66). These behaviors can be regarded as self-injury equivalents (11). Factitious disorder represents the extreme manifestation of this behavior, that is, a clandestine self-injury that is presented as illness or accidental injury. These patients can cause severe problems and conflicts in health care providers and institutions and frequently end up in a fruitless power struggle with the caretakers. In the literature, it has been stated repeatedly that patients with factitious disorder often also have BPD (67–69); however, a recent review revealed contradictory results (70).

An overview of comorbidity studies of BPD with somatic diseases is given in Table 1. BPD is associated with cardiovascular, metabolic, and gastrointestinal diseases as well as pain conditions, venereal diseases and HIV, urinary incontinence, and sleep disturbance. Of particular interest are the increased prevalences of cardiovascular disease in general (15.3%), pain conditions like arthritis (17.2%–27.7%) and chronic pain in general (62.5%–80.3%), gastrointestinal (21.1%) and hepatic (3.1%) disease, and urinary incontinence (18.8%) and venereal disease (3.1%). However, one of the biggest surveys (71) showed that the increased risk of diabetes, stroke, and obesity in patients with BPD is no longer significant when rigidly controlled for sociodemographics (sex, age in years, race/ethnicity, education, marital status, and past year’s household income) and psychiatric comorbidity (any anxiety, mood, or substance use disorder, and any PD other than borderline). Thus, it can be assumed that there are complex correlations between different psychosomatic components rather than unidirectional causal relationships. Nevertheless, all in all, patients with BPD show more somatic illness than do patients without BPD.

TABLE 1

TABLE 1

Back to Top | Article Outline

ETIOLOGY

BPD can be attributed to psychosocial and biological factors that interact in a complex way (88,89). More than 90% of the BPD patients are exposed to childhood maltreatment, abuse, and/or neglect (90,91). In a large prospective cohort study, low parental affection and aversive parental behavior in the early years of development have been shown to increase the risk of BPD in adulthood substantially (92). At the same time, a considerable heritability of 35% to 67% for BPD has been demonstrated in several studies, but so far, no direct role of genetic polymorphisms has been found (93). It is not BPD itself that is genetically determined but rather endophenotypes that predispose for the disorder, for example, impulsivity, aggression, affective dysregulation, or emotional information processing (94). These genetic vulnerabilities interact with environmental influences, and these interactions most probably shape biological abnormalities, neuropsychological impairment, and finally symptoms of BPD (93).

BPD goes along with a number of neurobiological alterations. First, specific changes in brain structure and brain function have been identified, and second, a number of neuroendocrine dysfunctions that exert influences on psychosomatic and somatic disorders occur. Neuroimaging studies have consistently revealed that BPD patients show an increased amygdala activity in combination with a decreased activity of dorsolateral prefrontal brain regions. These findings have been interpreted as neurobiological correlates of the emotional dysregulation in BPD (95,96).

A recent study gave hints on a cortical malfunction of the processing of bodily signals in BPD (97) patients that might foster the development of a number of somatic diseases due to an increased awareness of bodily changes. These probably take place in concert with neuroendocrine alterations, such as increased sympathetic activation and decreased parasympathetic deactivation under laboratory stress (98). Changes in hypothalamic-pituitary-adrenal (HPA) axis dysfunction have been reported in terms of increased salivary cortisol levels, increased total cortisol in response to awakening, increased total daily cortisol levels, and more nonsuppressors of cortisol in the low-dose dexamethasone suppression test (99). Because an association of methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity of BPD has been detected (100), a biopsychosocial genes–trauma–HPA axis interaction has been hypothesized (101). However, recently, it was shown that alterations of the HPA axis occur as a response to early maltreatment rather than as a consequence of comorbid BPD pathology (101,102). A few studies demonstrated increased testosterone levels in saliva after awakening (103) and in hair (104), as well as reduced plasma oxytocin in BPD women (105). The latter particularly occurs in BPD patients with unresolved (disorganized) attachment representations (106). Finally, differences between BPD patients and healthy controls have been found with regard to the μ-opioid receptor concentrations and the endogenous opioid system activation in response to negative emotional stimuli (107). It was hypothesized that BPD in itself represents a dysregulation of the endogenous opioid system (108); however, until now, this remains speculative (102).

Back to Top | Article Outline

TREATMENT

Empirically Validated Treatments

Treatment guidelines from the United States (109), the United Kingdom (110), and Germany (111) consentaneously mention psychotherapy as the treatment of choice for BPD. Moreover, the guidelines state that there is no pharmacological treatment of BPD itself; if drugs are given, they should aim at comorbid disorders and/or target symptoms such as severe impulsivity, anxiety, severe restlessness, or sleep disturbance (109–111). Recent reviews concluded that second-generation antipsychotics (e.g., lower-dose quetiapine), mood stabilizers, and dietary supplementation by omega-3 fatty acids may yield some beneficial effects on selected symptoms of BPD but will not change the personality. They might particularly be indicated when no evidence-based psychotherapy is available. Selective serotonin reuptake inhibitors have not been shown to be effective in BPD (112,113).

Four disorder-specific manualized psychotherapies have demonstrated their efficacy in randomized controlled trials (RCTs) (114): dialectical behavior therapy (DBT) (115), transference-focused psychotherapy (TFP) (116), mentalization-based therapy (MBT) (117), and schema-focused therapy (SFT) (118). DBT has been developed specifically as a treatment for the reduction of suicidal and self-harming behavior by applying skills training and specific cognitive behavioral techniques for the enhancement of emotion regulation (115). Compared with the other treatments, it has been investigated in the largest number of open trials and RCTs. A meta-analysis revealed moderate global effects and particularly moderate effect sizes for the reduction of suicidal and self-injurious behaviors (119). In an uncontrolled German study, a reduction of 50% of total societal costs was achieved in those 70% of patients who could be followed up 1 year after 12 months of DBT (44). TFP is a psychodynamic treatment that focuses on PF, particularly the integration of the self (identity) and quality of interpersonal relationships (116). It demonstrated its efficacy in a number of uncontrolled studies and two RCTs(120,121); particularly PF, mentalization, and attachment representations have been improved significantly (121–124). MBT also is a psychodynamic treatment that is usually delivered as a combination of individual and group therapy; it specifically aims at mentalization, that is, the ability to understand one’s own and others motives, feelings, and behaviors (117). MBT has been shown to be effective in a variety of uncontrolled studies and two RCTs; one took place in a day care unit setting with a considerable follow-up period of 8 years (125,126), the second one was an outpatient treatment study (127). Both yielded highly significant effects on general psychopathology, self-harming behavior, suicidality, and social functioning. SFT aims at the change of specific dysfunctional schema modes in BPD, that is, internal images of early relationship experiences such as mistrust/abuse, defectiveness/shame, angry child, impulsive child, by using behavioral, cognitive, and experimental techniques. SFT represents a cognitive behavioral treatment that has incorporated some aspects of psychodynamic theory and focuses primarily on relationship experiences in the present and past (118). SFT was found to effectively reduce general psychopathology, borderline symptoms, and quality of life in uncontrolled trails as well as in two RCTs; one used individual outpatient treatment (128), and the other one used outpatient group therapy (129).

In addition to the four manualized and empirically validated stand-alone treatments, the Systems Training for Emotional Predictability and Problem Solving is an add-on manualized group treatment program that has shown to be effective in BPD when combined with other forms of therapy (130,131). Recently, new treatments have been developed to be applied specifically in BPD as a basic psychiatric care. These treatments, good psychiatric management (GPM) (132) and structured clinical management (SCM) (133), are also manualized treatments that integrate basic attitudes and techniques from effective psychotherapies to be used in general mental health care by professionals without extended training. Preliminary evidence hints at an effectiveness of both treatments: SCM showed to be equally effective than MBT in major outcome variables of an RCT (127); GPM was compared with DBT in an RCT, and no significant differences between both groups were found in all primary and secondary outcomes (134,135). However, although easier to learn, these programs premise an experienced and interpersonally skilled clinician as well as a regular and structured setting with weekly contacts for 12 to 18 months or longer.

Although there is no doubt that psychotherapies are effective in BPD and can even change central aspects of the personality, evidence on the biobehavioral underpinnings of these changes is sparse. Three functional magnetic resonance imaging studies revealed that 12-week inpatient DBT resulted in specific changes in neuronal activity in DBT responders toward a more normal functioning (136–138). One study investigated changes in neuronal functioning before and after TFP and also yielded significant changes (139). These studies provide evidence for an influence of psychotherapy on brain function that tends to change toward normalized functioning. However, until now, there is no convincing theoretical model on how neuronal changes, psychotherapy, and behavioral changes interact and determine each other.

Back to Top | Article Outline

Implementation of Treatment Models

All of the four empirically validated BPD psychotherapies are taught in curricula in many countries. Networks or international societies exist and can easily be found on the internet or by approaching the authors of the manuals and efficacy studies. Usually, a training curriculum consists of a manageable amount of theoretical training and treatment for a patient under regular supervision; in general, a basic psychotherapeutic training or at least a license as psychiatrist or clinical psychologist is a prerequisite. The general psychiatric care models (GPM and SCM) are easier to learn, but it should be taken into consideration that a considerable experience as a mental health professional is essential and a setting allowing for regular appointments (as mentioned previously) is indispensable. Individual psychotherapists or psychiatrists can participate in training courses at regional institutes or attend introductory workshops at the conferences of the International Society for the Study of Personality Disorders (www.isspd.com), the North American Society for the Study of Personality Disorders (www.nasspd.org), or the European Society for the Study of Personality Disorders (www.esspd.eu), among others. All treatments can also be implemented by in-house trainings at institutions or clinical departments. Certified teachers and supervisors will be available to come to the sites for theoretical training and supervision; the latter is also provided online by many supervisors. MBT has been primarily developed as a day care unit treatment, and DBT and TFP have also been evaluated as inpatient treatments (140,141). For institutional teams in inpatient or day care units, a comprehensive training of the whole team is recommended to be able to develop a joint understanding and concept of intervention in the treatment for BPD patients; regular external supervision is indispensable.

Back to Top | Article Outline

CONCLUSIONS

BPD—like many other psychiatric disorders—can be regarded as a psychosomatic illness. Genetic disposition, early environmental stress, epigenetic makeup, neurobiological and neuroendocrine changes, and early relationship experiences interact with each other and lead to BPD pathology. Comorbidities of psychiatric and also of medical illnesses are frequent. Personality problems on the level of life-style and health behavior as well as the often troublesome interpersonal interactions with health professionals cause and/or facilitate highly complicated courses of somatic illnesses and their treatment. Health care professionals of any specialty should be aware of the challenging relationship with patients having BPD; being familiar with the pathology and its complications may be productive in adapting an interactive style that will benefit the therapeutic relationship. Awareness of available treatment resources and referral processes will promote both mental and medical health care. Health care professionals dealing with BPD patients would benefit from striving to learn one of the empirically validated treatment options, and teams and institutions should be aware of evidence-based treatments for BPD and make these treatments available to patients with BPD.

Source of Funding and Conflicts of Interest: No financial or other support was received by the author for preparing this manuscript. The author is a therapist and a supervisor of transference-focused psychotherapy.

Back to Top | Article Outline

REFERENCES

1. Huang Y, Kotov R, de Girolamo G, Preti A, Angermeyer M, Benjet C, Demyttenaere K, de Graaf R, Gureje O, Karam AN, Lee S, Lépine JP, Matschinger H, Posada-Villa J, Suliman S, Vilagut G, Kessler RC. DSM-IV personality disorders in the WHO World Mental Health Surveys. Br J Psychiatry 2009;195:46–53.
2. Jackson HJ, Burgess PM. Personality disorders in the community: a report from the Australian National Survey of Mental Health and Wellbeing. Soc Psychiatry Psychiatr Epidemiol 2000;35:531–8.
3. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;62:553–64.
4. ten Have M, Verheul R, Kaasenbrood A, van Dorsselaer S, Tuithof M, Kleinjan M, de Graaf R. Prevalence rates of borderline personality disorder symptoms: a study based on the Netherlands mental Health Survey and Incidence Study-2. BMC Psychiatry 2016;16:249.
5. Tomko RL, Trull TJ, Wood PK, Sher KJ. Characteristics of borderline personality disorder in a community sample: comorbidity, treatment utilization, and general functioning. J Pers Disord 2014;28:734–50.
6. Black DW, Blum N, Letuchy E, Carney Doebbeling C, Forman-Hoffman VL, Doebbeling BN. Borderline personality disorder and traits in veterans: psychiatric comorbidity, healthcare utilization, and quality of life along a continuum of severity. CNS Spectr 2006;11:680–9.
7. Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G, Weinberg I, Gunderson JG. The 10-year course of physically self-destructive acts reported by borderline patients and axis II comparison subjects. Acta Psychiatr Scand 2008;117:177–84.
8. Powers AD, Oltmanns TF. Personality disorders and physical health: a longitudinal examination of physical functioning, healthcare utilization, and health-related behaviors in middle-aged adults. J Pers Disord 2012;26:524–38.
9. Bender DS, Skodol AE, Pagano ME, Dyck IR, Grilo CM, Shea MT, Sanislow CA, Zanarini MC, Yen S, McGlashan TH, Gunderson JG. Prospective assessment of treatment use by patients with personality disorders. Psychiatr Serv 2006;57:254–7.
10. Keuroghlian AS, Gunderson JG, Pagano ME, Markowitz JC, Ansell EB, Shea MT, Morey LC, Sanislow C, Grilo CM, Stout RL, Zanarini MC, McGlashan TH, Skodol AE. Interactions of borderline personality disorder and anxiety disorders over 10 years. J Clin Psychiatry 2015;76:1529–34.
11. Sansone RA, Sansone LA. Borderline Personality disorder in the medical setting: suggestive behaviors, syndromes, and Diagnoses. Innov Clin Neurosci 2015;12:39–44.
12. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5. Washington, DC: American Psychiatric Association, American Psychiatric Press; 2013.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, DSM-IV. Washington, DC: American Psychiatric Press; 1994.
14. Hyler SE. Personality Questionnaire-4+. New York: State Psychiatric Institute; 1994.
15. Hyler SE, Skodol AE, Kellman HD, Oldham JM, Rosnick L. Validity of the Personality Diagnostic Questionnaire—Revised: comparison with two structured interviews. Am J Psychiatry 1990;147:1043–8.
16. Schotte CK, de Doncker D, Vankerckhoven C, Vertommen H, Cosyns P. Self-report assessment of the DSM-IV personality disorders. Measurement trait and distress characteristics: the ADP-IV. Psychol Med 1998;28:1179–88.
17. Bohus M, Limberger MF, Frank U, Chapman AL, Kuhler T, Stieglitz RD. Psychometric properties of the Borderline Symptom List (BSL). Psychopathology 2007;40:126–32.
18. Morey LC. Development and initial evaluation of a self-report form of the DSM-5 Level of Personality Functioning Scale. Psychol Assess 2017;29:1302–8.
19. Krueger RF, Derringer J, Markon KE, Watson D, Skodol AE. The Personality Inventory for DSM-5 (PID-5), Adult. Washington, DC: American Psychiatric Association; 2013: Available at: https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/assessment-measures#Personality.
20. First MB, Williams JBW, Benjamin LS, Spitzer RL. Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD). User’s Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: America Psychiatric Publishing; 2016.
21. Coid J, Yang M, Tyrer P, Roberts A, Ullrich S. Prevalence and correlates of personality disorder in Great Britain. Br J Psychiatry 2006;188:423–31.
22. Moran P, Coffey C, Mann A, Carlin JB, Patton GC. Personality and substance use disorders in young adults. Br J Psychiatry 2006;188:374–9.
23. Quirk SE, Berk M, Pasco JA, Brennan-Olsen SL, Chanen AM, Koivumaa-Honkanen H, Burke LM, Jackson HJ, Hulbert C, A Olsson C, Moran P, Stuart AL, Williams LJ. The prevalence, age distribution and comorbidity of personality disorders in Australian women. Aust N Z J Psychiatry 2017;51:141–50.
24. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001;58:590–6.
25. Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, Smith SM, Dawson DA, Pulay AJ, Pickering RP, Ruan WJ. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2008;69:533–45.
26. Gross R, Olfson M, Gameroff M, Shea S, Feder A, Fuentes M, Lantigua R, Weissman MM. Borderline personality disorder in primary care. Arch Intern Med 2002;162:53–60.
27. Hueston WJ, Werth J, Mainous AG. Personality disorder traits: prevalence and effects on health status in primary care patients. Int J Psychiatry Med 1999;29:63–74.
28. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry 2005;162:1911–8.
29. Zimmerman M, Mattia JI. Differences between clinical and research practices in diagnosing borderline personality disorder. Am J Psychiatry 1999;156:1570–4.
30. Pascual JC, Córcoles D, Castano J, Ginés JM, Gurrea A, Martín-Santos R, Garcia-Ribera C, Pérez V, Bulbena A. Hospitalization and pharmacotherapy for borderline personality disorder in a psychiatric emergency service. Psychiatr Serv 2009;58:1199–204.
31. Koenigsberg HW, Kaplan RD, Gilmore MM, Cooper AM. The relationship between syndrome and personality disorder in DSM-III: experience with 2,462 patients. Am J Psychiatry 1985;142:207–12.
32. Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. Hosp Community Psychiatry 1991;42:1015–21.
33. Gunderson JG. Borderline Personality Disorder. A Clinical Guide. Washington, DC: American Psychiatric Publishing; 2001.
34. Oldham JM. Borderline personality disorder and suicidality. Am J Psychiatry 2006;163:20–6.
35. Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, and prevention. J Pers Disord 2004;18:226–39.
36. Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, Shea MT, Zanarini MC, Oldham JM, Gunderson JG. Treatment utilization by patients with personality disorders. Am J Psychiatry 2001;158:295–302.
37. Zanarini MC, Frankenburg FR, Hennen J, Silk KR. Mental health service utilization by borderline personality disorder patients and axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65:28–36.
38. Coid J, Yang M, Bebbington P, Moran P, Brugha T, Jenkins R, Farrell M, Singleton N, Ullrich S. Borderline personality disorder: health service use and social functioning among a national household population. Psychol Med 2009;39:1721–31.
39. Ansell EB, Sanislow CA, McGlashan TH, Grilo CM. Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy control group. Compr Psychiatry 2007;48:329–36.
40. Cailhol L, Francois M, Thalamas C, Garrido C, Birmes P, Pourcel L, Lapeyre-Mestre M, Paris J. Is borderline personality disorder only a mental health problem? Personal Ment Health 2016;10:328–36.
41. Bode K, Vogel R, Walker J, Kröger C. Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. Eur J Health Econ 2017;18:1125–35.
42. Salvador-Carulla L, Bendeck M, Ferrer M, Andión O, Aragonès E, Casas Mfor the BPD-Cost Group. Cost of borderline personality disorder in Catalonia (Spain). Eur Psychiatry 2014;29:490–7.
43. Van Asselt AD, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder: societal cost of illness in BPD-patients. Eur Psychiatry 2007;22:354–61.
44. Wagner T, Fydrich T, Stiglmayr C, Marschall P, Salize HJ, Renneberg B, Fleßa S, Roepke S. Societal cost-of-illness in patients with borderline personality disorder one year before, during and after dialectical behavior therapy in routine outpatient care. Behav Res Ther 2014;61:12–22.
45. Jerschke S, Meixner K, Richter H, Bohus M. Zur Behandlungsgeschichte und Versorgungssituation von Patientinnen mit Borderline Persönlichkeitsstörung in der Bundesrepublik Deutschland. Fortschr Neurol Psychiatr 1998;66:545–52.
46. Meuldijk D, McCarthy A, Bourke ME, Grenyer BF. The value of psychological treatment for borderline personality disorder: systematic review and cost offset analysis of economic evaluations. PLoS One 2017;12:e0171592.
47. Jackson HJ, Burgess PM. Personality disorders in the community: results from the Australian National Survey of Mental Health and Well-Being part III. Soc Psychiatry Psychiatr Epidemiol 2004;39:765–76.
48. Skodol AE, Gunderson JG, McGlashan TH, Dyck IR, Stout RL, Bender DS, Grilo CM, Shea MT, Zanarini MC, Morey LC, Sanislow CA, Oldham JM. Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. Am J Psychiatry 2002;159:276–83.
49. Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. Acta Psychiatr Scand 2010;122:103–9.
50. Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, Zanarini MC, Yen S, Markowitz JC, Sanislow C, Ansell E, Pinto A, Skodol AE. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders study. Arch Gen Psychiatry 2011;68:827–37.
51. McGlashan TH, Grilo CM, Skodol AE, Gunderson JG, Shea MT, Morey LC, Zanarini MC, Stout RL. The Collaborative Longitudinal Personality Disorders Study: baseline axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand 2000;102:256–64.
52. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha AT, Levin A, Reynolds V. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998;155:1733–9.
53. Silverman MH, Frankenburg FR, Reich DB, Fitzmaurice G, Zanarini MC. The course of anxiety disorders other than PTSD in patients with borderline personality disorder and axis II comparison subjects: a 10-year follow-up study. J Pers Disord 2012;26:804–14.
54. Rosenvinge JH, Martinussen M, Ostensen E. The comorbidity of eating disorders and personality disorders: a meta-analytic review of studies published between 1983 and 1998. Eat Weight Disord 2000;5:52–61.
55. Zanarini MC, Reichman CA, Frankenburg FR, Reich DB, Fitzmaurice G. The course of eating disorders in patients with borderline personality disorder: a 10-year follow-up study. Int J Eat Disord 2010;43:226–32.
56. Garcia-Campayo J, Alda M, Sobradiel N, Olivan B, Pascual A. Personality disorders in somatization disorder patients: a controlled study in Spain. J Psychosom Res 2007;62:675–80.
57. Rost KM, Akins RN, Brown FW, Smith CR. The comorbidity of DSM-III-R personality disorders in somatization disorder. Gen Hosp Psychiatry 1992;14:322–6.
58. Hudziak JJ, Boffeli TJ, Kreisman JJ, Battaglia MM, Stanger C, Guze SB. Clinical study of the relation of borderline personality disorder to Briquet’s syndrome (hysteria), somatization disorder, antisocial personality disorder, and substance abuse disorders. Am J Psychiatry 1996;153:1598–606.
59. Frankenburg FR, Zanarini MC. Personality disorders and medical comorbidity. Curr Opin Psychiatry 2006;19:428–31.
60. Frankenburg FR, Zanarini MC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry 2004;65:1660–5.
61. Powers AD, Oltmanns TF. Personality pathology as a risk factor for negative health perception. J Pers Disord 2013;27:359–70.
62. Sansone RA, Bohinc RJ, Wiederman MW. Borderline personality symptomatology and compliance with general health care among internal medicine outpatients. Int J Psychiatry Clin Pract 2015;19:132–6.
63. Sansone RA, Farukhi S, Wiederman MW. Disruptive behaviors in the medical setting and borderline personality. Int J Psychiatry Med 2011;41:355–63.
64. Sansone RA, Wiederman MW, Sansone LA. Medically self-harming behavior and its relationship to borderline personality symptoms and somatic preoccupation among internal medicine patients. J Nerv Ment Dis 2000;188:45–7.
65. Sansone RA, Lam C, Wiederman MW. Preventing wounds from healing: a relationship with borderline personality? Int J Psychiatry Med 2010;40:469–71.
66. Sansone RA, Chang J, Jewell B. Preventing wounds from healing and borderline personality symptomatology. Prim Care Companion CNS Disord 2012;14.
67. Freyberger H, Nordmeyer JP, Freyberger HJ, Nordmeyer J. Patients suffering from factitious disorders in the clinico-psychosomatic consultation liaison service: psychodynamic processes, psychotherapeutic initial care and clinicointerdisciplinary cooperation. Psychother Psychosom 1994;62:108–22.
68. Rothenhäusler HB, Kapfhammer HP. Zur Frage des Zusammenhangs zwischen vorgetäuschter Störung und Persönlichkeitsstörung. Persönlichkeitsstörungen 2005;9:99–105.
69. Gordon DK, Sansone RA. A relationship between factitious disorder and borderline personality disorder. Innov Clin Neurosci 2013;10:11–3.
70. Yates GP, Feldman MD. Factitious disorder: a systematic review of 455 cases in the professional literature. Gen Hosp Psychiatry 2016;41:20–8.
71. El-Gabalawy R, Katz LY, Sareen J. Comorbidity and associated severity of borderline personality disorder and physical health conditions in a nationally representative sample. Psychosom Med 2010;72:641–7.
72. Greggersen W, Rudolf S, Brandt PW, Schulz E, Fassbinder E, Willenborg B, Kahl KG, Bergmann-Koester C, Stoeckelhuber BM, Hohagen F, Schweiger U. Intima-media thickness in women with borderline personality disorder. Psychosom Med 2011;73:627–32.
73. Lee HB, Bienvenu OJ, Cho SJ, Ramsey CM, Bandeen-Roche K, Eaton WW, Nestadt G. Personality disorders and traits as predictors of incident cardiovascular disease: findings from the 23-year follow-up of the Baltimore ECA study. Psychosomatics 2010;51:289–96.
74. Moran P, Stewart R, Brugha T, Bebbington P, Bhugra D, Jenkins R, Coid JW. Personality disorder and cardiovascular disease: results from a national household survey. J Clin Psychiatry 2007;68:69–74.
75. Powers AD, Oltmanns TF. Borderline personality pathology and chronic health problems in later adulthood: the mediating role of obesity. Personal Disord 2013;4:152–9.
76. Tully PJ, Selkow T. Personality disorders in heart failure patients requiring psychiatric management: comorbidity detections from a routine depression and anxiety screening protocol. Psychiatry Res 2014;220:954–9.
77. Kahl K, Greggersen W, Schweiger U, Cordes J, Correll CU, Frieling H, Balijepalli C, Lösch C, Moebus S. Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. Eur Arch Psychiatry Clin Neurosci 2013;263:205–13.
78. Biskin RS, Frankenburg FR, Fitzmaurice GM, Zanarini MC. Pain in patients with borderline personality disorder. Personal Ment Health 2014;8:218–27.
79. Fischer-Kern M, Kapusta ND, Doering S, Hörz S, Mikutta C, Aigner M. The relationship between personality organization and psychiatric classification in chronic pain patients. Psychopathology 2011;44:21–6.
80. McWilliams LA, Higgins KS. Associations between pain conditions and borderline personality disorder symptoms: findings from the National Comorbidity Survey Replication. Clin J Pain 2013;29:527–32.
81. Polatin PB, Kinney RK, Gatchel RJ, Lillo E, Mayer TG. Psychiatric illness and chronic low-back pain. The mind and the spine—which goes first? Spine (Phila Pa 1976) 1993;18:66–71.
82. Reynolds CJ, Carpenter RW, Tragesser SL. Accounting for the association between BPD features and chronic pain complaints in a pain patient sample: the role of emotion dysregulation factors. Personal Disord 2018;9:284–9.
83. Rothrock J, Lopez I, Zweilfer R, Andress-Rothrock D, Drinkard R, Walters N. Borderline personality disorder and migraine. Headache 2007;47:22–6.
84. Tan RY, Grigg J, Kulkarni J. Borderline personality disorder and polycystic ovary syndrome: a review of the literature. Aust N Z J Psychiatry 2018;52:117–28.
85. Lopes M, Olfson M, Rabkin J, Hasin DS, Alegría AA, Lin KH, Grant BF, Blanca C. Gender, HIV status, and psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2012;73:384–91.
86. Bennett WR, Joesch JM, Mazur M, Roy-Byrne P. Characteristics of HIV-positive patients treated in a psychiatric emergency department. Psychiatr Serv 2009;60:398–401.
87. Winsper C, Tang NK, Marwaha S, Lereya ST, Gibbs M, Thompson A, Singh SP. The sleep phenotype of borderline personality disorder: a systematic review and meta-analysis. Neurosci Biobehav Rev 2017;73:48–67.
88. Hughes AE, Crowell SE, Uyeji L, Coan JA. A developmental neuroscience of borderline pathology: emotion dysregulation and social baseline theory. J Abnorm Child Psychol 2012;40:21–33.
89. Cattane N, Rossi R, Lanfredi M, Cattaneo A. Borderline personality disorder and childhood trauma: exploring the affected biological systems and mechanisms. BMC Psychiatry 2017;17:221.
90. Zanarini MC, Williams AA, Lewis RE, Reich RB, Vera SC, Marino MF, Levin A, Yong L, Frankenburg FR. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997;154:1101–6.
91. Battle CL, Shea MT, Johnson DM, Yen S, Zlotnick C, Zanarini MC, Sanislow CA, Skodol AE, Gunderson JG, Grilo CM, McGlashan TH, Morey LC. Childhood maltreatment associated with adult personality disorders: findings from the collaborative longitudinal personality disorders study. J Pers Disord 2004;18:193–211.
92. Johnson JG, Cohen P, Chen H, Kasen S, Brook JS. Parenting behaviors associated with risk for offspring personality disorder during adulthood. Arch Gen Psychiatry 2006;63:579–87.
93. Amad A, Ramoz N, Thomas P, Jardri R, Gorwood P. Genetics of borderline personality disorder: systematic review and proposal of an integrative model. Neurosci Biobehav Rev 2014;40:6–19.
94. Siever LJ. Endophenotypes in the personality disorders. Dialogues Clin Neurosci 2005;7:139–51.
95. Krause-Utz A, Winter D, Niedtfeld I, Schmahl C. The latest neuroimaging findings in borderline personality disorder. Curr Psychiatry Rep 2014;16:438.
96. Schulze L, Schmahl C, Niedtfeld I. Neural correlates of disturbed emotion processing in borderline personality disorder: a multimodal meta-analysis. Biol Psychiatry 2016;79:97–106.
97. Müller LE, Schulz A, Andermann M, Gäbel A, Gescher DM, Spohn A, Herpertz SC, Bertsch K. Cortical representation of afferent bodily signals in borderline personality disorder. JAMA Psychiat 2015;72:1077–86.
98. Weinberg A, Klonsky ED, Hajcak G. Autonomic impairment in borderline personality disorder: a laboratory investigation. Brain Cogn 2009;71:279–86.
99. Lieb K, Rexhausen JE, Kahl KG, Schweiger U, Philipsen A, Hellhammer DH, Bohus M. Increased diurnal salivary cortisol in women with borderline personality disorder. J Psychiatr Res 2004;38:559–65.
100. Martín-Blanco A, Ferrer M, Soler J, Salazar J, Vega D, Andión O, Sanchez-Mora C, Arranz MJ, Ribases M, Feliu-Soler A, Pérez V, Pascual JC. Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. J Psychiatr Res 2014;57:34–40.
101. Martín-Blanco A, Ferrer M, Soler J, Arranz MJ, Vega D, Calvo N, Elices M, Sanchez-Mora C, García-Martinez I, Salazar J, Carmona C, Bauzà J, Prat M, Pérez V, Pascual JC. The role of hypothalamus-pituitary-adrenal genes and childhood trauma in borderline personality disorder. Eur Arch Psychiatry Clin Neurosci 2016;266:307–16.
102. Kaess M, Whittle S, Simmons JG, Jovev M, Allen NB, Chanen AM. The interaction of childhood maltreatment, sex, and borderline personality features in the prediction of the cortisol awakening response. Psychopathology 2017;50:188–94.
103. Rausch J, Gäbel A, Nagy K, Kleindienst N, Herpertz SC, Bertsch K. Increased testosterone levels and cortisol awakening responses in patients with borderline personality disorder: gender and trait aggressiveness matter. Psychoneuroendocrinology 2015;55:116–27.
104. Dettenborn L, Kirschbaum C, Gao W, Spitzer C, Roepke S, Otte C, Wingenfeld K. Increased hair testosterone but unaltered hair cortisol in female patients with borderline personality disorder. Psychoneuroendocrinology 2016;71:176–9.
105. Bertsch K, Schmidinger I, Neumann ID, Herpertz SC. Reduced plasma oxytocin levels in female patients with borderline personality disorder. Horm Behav 2013;63:424–9.
106. Jobst A, Padberg F, Mauer MC, Daltrozzo T, Bauriedl-Schmidt C, Sabass L, Sarubin N, Falkai P, Renneberg B, Zill P, Gander M, Buchheim A. Lower oxytocin plasma levels in borderline patients with unresolved attachment representations. Front Hum Neurosci 2016;10:125.
107. Prossin AR, Love TM, Koeppe RA, Zubieta JK, Silk KR. Dysregulation of regional endogenous opioid function in borderline personality disorder. Am J Psychiatry 2010;167:925–33.
108. Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev 2010;117:623–36.
109. Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Washington, DC: American Psychiatric Association, American Psychiatric Association; 2001.
110. National Institute for Health and Care Excellence (NICE). Borderline Personality Disorder: Recognition and Management. Manchester: National Institute for Health and care Excellence; 2009.
111. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Neurologie. Behandlungsleitlinie Persönlichkeitsstörungen. Darmstadt: Steinkopff Verlag; 2009.
112. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010;6:CD005653.
113. Stoffers JM, Lieb K. Pharmacotherapy for borderline personality disorder—current evidence and recent trends. Curr Psychiatry Rep 2015;17:534.
114. Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2012;8:CD005652.
115. Linehan MM. Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York, NY: Guilford Press; 1993.
116. Yeomans F, Clarkin JF, Kernberg OF, Kernberg OF. Transference-Focused Psychotherapy for Borderline Personality Disorder: A Clinical Guide. Arlington, VA: American Psychiatric Publishing; 2015.
117. Bateman A, Fonagy A. Psychotherapy for Borderline Personality Disorder. Mentalization-Based Treatment. Oxford: Oxford University Press; 2004.
118. Young JE. Cognitive Therapy for Personality Disorders: A Schema-Focused Approach. 3rd ed. Sarasota, FL: Professional Resource Press; 1999.
119. Kliem S, Kröger C, Kosfelder J. Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling. J Consult Clin Psychol 2010;78:936–51.
120. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry 2007;164:922–8.
121. Doering S, Hörz S, Rentrop M, Fischer-Kern M, Schuster P, Benecke C, Buchheim A, Martius P, Buchheim P. Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. Br J Psychiatry 2010;196:389–95.
122. Levy KN, Meehan KB, Kelly KM, Reynoso JS, Weber M, Clarkin JF, Kernberg OF. Change in attachment patterns and reflective function in a randomized control trial of transference-focused psychotherapy for borderline personality disorder. J Consult Clin Psychol 2006;74:1027–40.
123. Fischer-Kern M, Doering S, Taubner S, Hörz S, Zimmermann J, Rentrop M, Schuster P, Buchheim P, Buchheim A. Transference-focused psychotherapy for borderline personality disorder: change in reflective function. Br J Psychiatry 2015;207:173–4.
124. Buchheim A, Hörz-Sagstetter S, Doering S, Rentrop M, Schuster P, Buchheim P, Pokorny D, Fischer-Kern M. Change of unresolved attachment in borderline personality disorder: RCT study of transference-focused psychotherapy. Psychother Psychosom 2017;86:314–6.
125. Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 2001;158:36–42.
126. Bateman A, Fonagy P. 8-Year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry 2008;165:631–8.
127. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry 2009;166:1355–64.
128. Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, Kremers I, Nadort M, Arntz A. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs. transference-focused psychotherapy. Arch Gen Psychiatry 2006;63:649–58.
129. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry 2009;40:317–28.
130. Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, Arndt S, Black DW. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry 2008;165:468–78.
131. Bos EH, van Wel EB, Appelo MT, Verbraak MJ. A randomized controlled trial of a Dutch version of systems training for emotional predictability and problem solving for borderline personality disorder. J Nerv Ment Dis 2010;198:299–304.
132. Gunderson J. Handbook of Good Psychiatric Management for Borderline Personality Disorder. Arlington, VA: American Psychiatric Publishing; 2014.
133. Bateman AW, Krawitz R. Borderline personality disorder. An evidence-based guide for generalist mental health professionals. Oxford: Oxford University Press; 2013.
134. McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, Streiner DL. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry 2009;166:1365–74.
135. McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS. Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry 2012;169:650–61.
136. Schnell K, Herpertz SC. Effects of dialectical behavior therapy on the neural correlates of affective hyperarousal in borderline personality disorder. J Psychiatr Res 2007;41:837–47.
137. Winter D, Niedtfeld I, Schmitt R, Bohus M, Schmahl C, Herpertz SC. Neural correlates of distraction in borderline personality disorder before and after dialectical behavior therapy. Eur Arch Psychiatry Clin Neurosci 2017;267:51–62.
138. Niedtfeld I, Schmitt R, Winter D, Bohus M, Schmahl C, Herpertz SC. Pain-mediated affect regulation is reduced after dialectical behavior therapy in borderline personality disorder: a longitudinal fMRI study. Soc Cogn Affect Neurosci 2017;12:739–47.
139. Perez DL, Vago DR, Pan H, Root J, Tuescher O, Fuchs BH, Leung L, Epstein J, Cain NM, Clarkin JF, Lenzenweger MF, Kernberg OF, Levy KN, Silbersweig DA, Stern E. Frontolimbic neural circuit changes in emotional processing and inhibitory control associated with clinical improvement following transference-focused psychotherapy in borderline personality disorder. Psychiatry Clin Neurosci 2016;70:51–61.
140. Bohus M, Haaf B, Simms T, Limberger MF, Schmahl C, Unckel C, Lieb K, Linehan MM. Effectiveness of inpatient dialectical behavior therapy for borderline personality disorder: a controlled trial. Behav Res Ther 2004;42:487–99.
141. Sollberger D, Gremaud-Heitz D, Riemenschneider A, Agarwalla P, Benecke C, Schwald O, Küchenhoff J, Walter M, Dammann G. Change in identity diffusion and psychopathology in a specialized inpatient treatment for borderline personality disorder. Clin Psychol Psychother 2015;22:559–69.

1The case is not one individual real case but a merger of several similar cases; thus, there is no threat to anonymity of an individual person.
Cited Here...

Keywords:

borderline personality disorder; somatic illness; epidemiology; comorbidity; treatment; implementation; AMPD = Alternative DSM-5 Model for Personality Disorders; BPD = borderline personality disorder; DBT = dialectical behavior therapy; DSM-5 = Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition); GPM = good psychiatric management; HPA = hypothalamic–pituitary–adrenal; MBT = mentalization-based therapy; PD = personality disorder; PF = personality functioning; RCT = randomized controlled trial; SCM = structured clinical management; SFT = schema-focused therapy; TFP = transference-focused psychotherapy

Copyright © 2019 by American Psychosomatic Society